IRIS
CORALLO, SALVATORE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 680
NA - Nord America 650
EU - Europa 501
SA - Sud America 143
AF - Africa 20
OC - Oceania 1
Totale 1.995
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 619
SG - Singapore 228
CN - Cina 199
HK - Hong Kong 146
RU - Federazione Russa 145
BR - Brasile 123
DE - Germania 97
IT - Italia 89
GB - Regno Unito 45
VN - Vietnam 35
FI - Finlandia 32
PL - Polonia 20
AT - Austria 17
CA - Canada 16
BD - Bangladesh 13
FR - Francia 13
IN - India 13
MX - Messico 12
AR - Argentina 9
ES - Italia 9
JP - Giappone 8
IQ - Iraq 7
SE - Svezia 7
EC - Ecuador 5
MA - Marocco 5
PK - Pakistan 5
TR - Turchia 5
ZA - Sudafrica 5
AE - Emirati Arabi Uniti 4
LT - Lituania 4
NL - Olanda 4
TN - Tunisia 4
AO - Angola 3
BE - Belgio 3
IE - Irlanda 3
SA - Arabia Saudita 3
AL - Albania 2
AZ - Azerbaigian 2
BG - Bulgaria 2
CO - Colombia 2
DO - Repubblica Dominicana 2
LV - Lettonia 2
PE - Perù 2
TH - Thailandia 2
UZ - Uzbekistan 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DZ - Algeria 1
EE - Estonia 1
IL - Israele 1
IR - Iran 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
PT - Portogallo 1
RO - Romania 1
SY - Repubblica araba siriana 1
UA - Ucraina 1
VE - Venezuela 1
Totale 1.995
Salva come PNG Salva come JPEG
Città #
Dallas 163
Hong Kong 146
Singapore 90
Beijing 87
Ashburn 82
Los Angeles 42
Munich 34
Redondo Beach 31
Turku 28
New York 26
Nuremberg 26
Buffalo 20
Moscow 19
Warsaw 19
São Paulo 18
Falkenstein 16
Ho Chi Minh City 13
Denver 12
Milan 11
Düsseldorf 10
Hanoi 9
Santa Clara 9
Brooklyn 8
Montreal 8
Orem 8
Tokyo 8
Atlanta 7
Chicago 7
Houston 7
Mexico City 7
Stockholm 7
Boston 6
Chennai 6
Council Bluffs 6
Nova Milanese 6
Poplar 6
San Jose 6
Vienna 6
London 5
Manchester 5
Pavia 5
Portsmouth 5
Ankara 4
Belo Horizonte 4
Biên Hòa 4
Da Nang 4
Frankfurt am Main 4
Helsinki 4
Johannesburg 4
Oujda 4
Phoenix 4
Rio de Janeiro 4
Seattle 4
Secaucus 4
Brasília 3
Brussels 3
Cagliari 3
Changsha 3
Desio 3
Dublin 3
Hyderabad 3
Londrina 3
Naples 3
San Francisco 3
Toronto 3
Vancouver 3
Zhoukou 3
Baku 2
Bangkok 2
Biassono 2
Boardman 2
Campinas 2
Chapecó 2
Charlotte 2
Columbus 2
Dubai 2
Duque de Caxias 2
Florence 2
Genoa 2
Haiphong 2
Helena 2
Islamabad 2
Manassas 2
Piracicaba 2
Pirapora do Bom Jesus 2
Porto Alegre 2
Ravenna 2
Riga 2
Riyadh 2
Rome 2
Salvador 2
Santa Maria 2
Savignano sul Rubicone 2
Senago 2
Shanghai 2
Shijiazhuang 2
Tashkent 2
Tianjin 2
Topeka 2
Vistarino 2
Totale 1.193
Salva come PNG Salva come JPEG
Nome #
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 115
Should we exclude patients with peritoneal carcinosis of colorectal origin and high PCI from CRS + HIPEC? 77
Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study 77
Metronomic capecitabine plus cyclophosphamide in unresectable or relapsed pseudomyxoma peritonei 77
First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study 64
Chemotherapy-induced changes in plasma amino acids and lipid oxidation of resected patients with colorectal cancer: a background for future studies 64
Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization 53
Pink-on-pink: hepatocellular carcinoma metastatic to oncocytic carcinoma of the thyroid 52
Vaccine hesitancy in patients with solid tumors: a cross-sectional single-center survey 47
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S 47
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients (pts) bearing MGMT methylation 45
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial 45
Vascular endothelial growth factor A (VEGF-A) amplification and long-term response to ramucirumab (ram) in metastatic gastric cancer (mGC): The VERA study 44
Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review 44
Circulating Tumor DNA Analysis in Colorectal Cancer: From Dream to Reality 44
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer 41
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study 40
Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study 40
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 39
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study 39
Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial 38
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 37
Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer: The AVANA study 36
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 35
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer 34
Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials 33
Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective 32
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 30
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study 30
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer A Subgroup Analysis of the TOSCA Randomized Clinical Trial 28
The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer 27
Case Report: Epstein-Barr virus negative lymphoepithelioma-like cholangiocarcinoma: a rare tumor that deserves further exploration. Report of a case with distinct genomic and clinical features 27
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase 26
Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan 25
The Key Role of Patient Empowerment in the Future Management of Cancer-Related Malnutrition 24
BRCA2-Related Hereditary Cancer Syndrome-Associated Small Bowel Adenocarcinoma With Multiple BRCA2 Mutations: A Case Report and Review of the Literature 24
The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials 24
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study 24
Transient receptor potential ankyrin 1 (TRPA1) mediates reactive oxygen species-induced Ca2+ entry, mitochondrial dysfunction, and caspase-3/7 activation in primary cultures of metastatic colorectal carcinoma cells 24
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy 23
Nutritional support management in resectable gastric cancer 23
Treatment options for EGFR T790M-negative egfr tyrosine kinase inhibitor-resistant non-small cell lung cancer 22
Oligometastatic colorectal cancer: Prognostic implications of tumor load, role of locoregional treatments, and of first-line therapy intensification-A pooled analysis of TRIBE and TRIBE2 studies by GONO 22
The Italian Rare Biliary tract Cancer initiative (IRaBiCa): A multicentric observational study of Gruppo Oncologico dell’Italia Meridionale (GOIM) in collaboration with Gruppo Italiano Colangiocarcinoma (GICO) 20
Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas 20
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study 19
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei 19
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation 19
Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases 19
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer 19
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study 18
The impact of multidisciplinary team management on outcome of hepatic resection in liver-limited colorectal metastases 18
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study 18
Adenomyoma/adenomyomatosis-associated mural intracholecystic neoplasms: analysis of clinico-pathologic, imaging, and molecular features of a consecutive case series 18
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 17
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 16
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial 16
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 15
Mucinous cystic neoplasms of the liver: Literature review and case series 15
HER2, HER3, and Mismatch Repair Protein Expression in Stage IV Small Bowel Adenocarcinoma: Results From a Multicenter Series 14
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 13
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come 8
null 2
Totale 2.065
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.104
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.104
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202422 12 1 2 0 1 0 2 2 0 1 1 0
2024/2025866 1 1 29 2 51 61 100 47 217 61 90 206
2025/20261.177 163 145 150 321 276 122 0 0 0 0 0 0
Totale 2.065